{"gene":"FHIT","run_date":"2026-06-09T23:54:43","timeline":{"discoveries":[{"year":1997,"finding":"Fhit hydrolyzes dinucleotide 5',5'''-P1,P3-triphosphate (Ap3A) in vitro; mutation of the central histidine abolishes hydrolase activity. However, both wild-type and hydrolase-dead Fhit mutant proteins suppressed tumorigenicity in nude mice, indicating that Ap3A hydrolysis is not required for tumor suppression.","method":"In vitro enzymatic assay; active-site mutagenesis; nude mouse tumorigenicity assay with FHIT-transfected cancer cell lines","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro enzymatic reconstitution combined with active-site mutagenesis and in vivo tumorigenicity assay in a single rigorous study","pmids":["9391102"],"is_preprint":false},{"year":2004,"finding":"Fhit is a physiological substrate of the Src protein kinase; Src phosphorylates Fhit at tyrosine 114 (Y114) both in vitro and in vivo, placing Fhit in a Src-dependent signaling pathway.","method":"In vitro kinase assay; in vivo phosphorylation; site-directed mutagenesis identifying Y114 as the phosphorylation site","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro kinase assay plus in vivo phosphorylation with site identification, single lab but two orthogonal methods","pmids":["15007172"],"is_preprint":false},{"year":2006,"finding":"Fhit Y114 is essential for caspase-dependent apoptosis; wild-type Fhit (but not Y114 mutants) inhibits Akt activity and reduces survivin expression in lung cancer cells, placing Fhit upstream of the PI3K-Akt-survivin survival pathway.","method":"Adenoviral expression of wild-type vs. Y114 mutant FHIT in lung cancer cell lines; caspase activation assays; expression profiling; Akt activity measurement in vitro and in vivo; constitutively active Akt rescue experiment","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (expression profiling, kinase activity, rescue with constitutively active Akt, mutagenesis) in a single focused study","pmids":["16407838"],"is_preprint":false},{"year":2006,"finding":"Fhit modulates expression of checkpoint proteins Hus1 and phospho-Chk1 at mid-S phase; exogenous Fhit introduction induces apoptosis in esophageal cancer cells through this checkpoint modulation, and Y114 mutation abolishes this function.","method":"Exogenous Fhit expression in cancer cell lines; Western blot for Hus1 and phospho-Chk1; Y114 mutagenesis; apoptosis assays","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean KO/overexpression with defined molecular readout and mutagenesis, single lab","pmids":["17145874"],"is_preprint":false},{"year":2007,"finding":"Fhit associates with the LEF1/TCF/β-catenin complex by directly binding to the β-catenin C-terminal domain, repressing transcription of Wnt target genes (cyclin D1, axin2, MMP-14, survivin); this function does not require Fhit's hydrolase activity; Fhit/β-catenin complexes are recruited to target gene promoters.","method":"Co-immunoprecipitation; ChIP; Fhit knockdown and double knockdown with β-catenin; reporter assays; soft-agar anchorage-independent growth assay; enzymatically inactive Fhit-H96N mutant","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP, ChIP, genetic rescue experiments, mutagenesis, and functional assay in one study","pmids":["18077326"],"is_preprint":false},{"year":2008,"finding":"Fhit interacts with Hsp60/Hsp10 chaperone machinery (identified by chemical cross-linking and immunoprecipitation), and with ferredoxin reductase (Fdxr) in mitochondria; Fhit binds and stabilizes Fdxr, and this interaction promotes reactive oxygen species production and apoptosis under oxidative stress. Substrate-binding and Y114 phosphorylation-competent Fhit mutants are required for Hsp60 and Fdxr interactions and for mitochondrial localization.","method":"Chemical cross-linking; co-immunoprecipitation; mutagenesis of substrate-binding and Y114 residues; subcellular fractionation; flow cytometry for ROS and apoptosis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — chemical cross-linking plus co-IP, mutagenesis, subcellular fractionation, and functional ROS/apoptosis assays in one rigorous study","pmids":["19004824"],"is_preprint":false},{"year":2012,"finding":"Loss of Fhit expression causes DNA replication stress-induced double-strand breaks; Fhit-deficient cells show defective replication fork progression (fork stalling and collapse by DNA combing); the mechanism involves Fhit regulation of Thymidine Kinase 1 (TK1) expression and thymidine triphosphate pool levels—restoration of nucleotide balance rescues replication defects and suppresses DNA breakage.","method":"DNA combing (single-molecule replication fork analysis); siRNA knockdown; TK1 expression measurement; thymidine supplementation rescue; γH2AX foci; Fhit knockout mouse tissue analysis","journal":"PLoS genetics","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — multiple orthogonal methods (DNA combing, molecular rescue, in vivo knockout tissue), replicated across normal, transformed, and cancer-derived cell lines","pmids":["23209436"],"is_preprint":false},{"year":2012,"finding":"Fhit's ability to prevent DNA damage requires a functional HIT domain and Y114 residue, and depends on Chk1 kinase activity but is independent of ATR or ATM kinases, suggesting Fhit and Chk1 cooperate to prevent replication stress-induced DNA damage.","method":"HIT domain mutants; Y114 mutant; Chk1, ATR, ATM inhibitors/knockdown; DNA damage markers in Fhit-deficient cells","journal":"Advances in biological regulation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacologic and genetic dissection of pathway dependencies, single lab, multiple inhibitor approaches","pmids":["23102829"],"is_preprint":false},{"year":2009,"finding":"Fhit localizes to both cytoplasm and mitochondria (but not nuclei) in normal tissue; Fhit-positive cancer cells exposed to oxidative stress (H2O2) produce higher levels of apoptosis-inducing ROS than matched Fhit-negative cells, a function linked to Fhit stabilization of mitochondrial Fdxr.","method":"Subcellular fractionation of normal and cancer cells; H2O2 treatment; ROS measurement; apoptosis assays in matched Fhit-positive vs. Fhit-negative cancer cells","journal":"Cancer science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — fractionation with functional consequence, matched cell pair comparisons, single lab","pmids":["19486340"],"is_preprint":false},{"year":2001,"finding":"Fhit protein is localized to the nucleus and plasma membrane in rat tissues (by differential and density-gradient centrifugation of subcellular fractions), with expression levels varying by tissue type (highest in spleen and brain).","method":"Differential and density-gradient centrifugation; immunoblot of subcellular fractions; RT-PCR","journal":"Molecular and cellular biochemistry","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single fractionation study without functional consequence linked to localization; contradicted by later mitochondrial/cytoplasmic localization findings","pmids":["11768238"],"is_preprint":false},{"year":2015,"finding":"Fhit loss-induced replication stress creates single-stranded DNA substrates optimal for APOBEC3B-mediated mutagenesis; FHIT-low/APOBEC3B-high tumors show significantly more APOBEC-signature mutations, and thymidine supplementation (rescuing TK1-dependent nucleotide imbalance) reduces APOBEC-directed TP53 mutations in vitro.","method":"TCGA data analysis correlated with in vitro Fhit knockdown; APOBEC3B-directed mutation assay in TP53; thymidine supplementation rescue","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mechanistic in vitro rescue experiment combined with TCGA correlative data, single lab","pmids":["25401976"],"is_preprint":false},{"year":2014,"finding":"FHIT suppresses EMT and metastasis in lung cancer by upregulating miR-30c, which directly targets metastasis genes MTDH, HMGA2, VIM, and FN1; enforced FHIT expression reduces invasiveness in vivo and in vitro.","method":"In vivo metastasis assay; in vitro invasion assay; miR-30c target validation; ectopic FHIT expression; FHIT/miR-30c/target expression correlation in human tumors","journal":"PLoS genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (in vivo and in vitro assays, miRNA target validation), single lab","pmids":["25340791"],"is_preprint":false},{"year":2014,"finding":"Fhit silencing in bronchial cells induces overexpression of MMP-9 and vimentin (EMT markers) via an EGFR/Src/ERK/Slug signaling axis; ectopic Fhit expression in Fhit-deficient lung cancer cells downregulates this pathway.","method":"Fhit siRNA knockdown; pharmacologic inhibitors (PD98059, PP1, gefitinib); anti-EGFR antibody; Slug knockdown; ectopic Fhit expression; IHC of human tumor specimens for Fhit/phospho-EGFR correlation","journal":"Molecular cancer research : MCR","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacologic and genetic pathway dissection with multiple inhibitors, single lab","pmids":["24464917"],"is_preprint":false},{"year":2006,"finding":"Fhit expression inhibits NF-κB signaling in colon cancer cells by reducing phosphorylation of IκB-α; FHIT-expressing cells show reduced basal p-IκB-α and attenuated NF-κB p65 phosphorylation in response to TNF-α.","method":"Stable FHIT transfection; FHIT siRNA knockdown; Western blot for IKK complex and p-IκB-α; TNF-α stimulation; NF-κB inhibitor sensitivity assays","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain- and loss-of-function experiments with defined molecular readout, single lab","pmids":["16733051"],"is_preprint":false},{"year":2006,"finding":"Fhit expression enhances paclitaxel-induced apoptosis through activation of caspase-3 and caspase-7 (but not caspase-8) and modulation of Bcl-2 family proteins (downregulation of Bcl-2/Bcl-xL; upregulation of Bax/Bad); this effect is reversed by FHIT siRNA.","method":"Stable FHIT transfection; FHIT siRNA; caspase activity assays; Western blot for Bcl-2 family; pan-caspase inhibitor","journal":"International journal of cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain- and loss-of-function with multiple molecular readouts, single lab","pmids":["16231322"],"is_preprint":false},{"year":2009,"finding":"Fhit and Nit1 tumor suppressor activities are additive in vivo (double-knockout mice develop more tumors than single knockouts), but Fhit and Nit1 affect distinct signal pathways in mammals; both proteins localize to cytoplasm and mitochondria but not nuclei.","method":"Fhit(-/-)Nit1(-/-) double-knockout mouse tumor susceptibility study; subcellular localization by fractionation; hydroxyurea and H2O2 treatment of double-deficient cells","journal":"Journal of cellular biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis via double-knockout mouse model with defined phenotypic readout, single lab","pmids":["19479888"],"is_preprint":false},{"year":2000,"finding":"Recombinant human Fhit protein is a homodimeric Ap3A asymmetric hydrolase with Km = 0.9 µM and kcat = 7.2 s⁻¹ per monomer, as measured by in vitro enzymatic assay of E. coli-expressed purified protein.","method":"Recombinant protein expression in E. coli; His-tag purification; in vitro enzymatic assay (Ap3A hydrolysis kinetics)","journal":"Protein expression and purification","confidence":"High","confidence_rationale":"Tier 1 / Moderate — rigorous in vitro reconstitution with kinetic characterization of purified protein, single lab","pmids":["10733886"],"is_preprint":false},{"year":2019,"finding":"FHIT acts as a modifier of BMPR2 signaling; FHIT reduction is associated with endothelial and smooth muscle cell dysfunction in pulmonary arterial hypertension, and Fhit-/- mice show exaggerated hypoxic pulmonary hypertension and failed recovery.","method":"siRNA high-throughput screen of >20,000 genes identifying FHIT as BMPR2 modifier; Fhit-/- mouse hypoxia model; in vitro cell dysfunction assays","journal":"American journal of respiratory and critical care medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genome-scale screen with in vivo validation in knockout mice, single lab","pmids":["30107138"],"is_preprint":false},{"year":2004,"finding":"Fhit-deficient cells (human cancer and Fhit-/- mouse) are ~10-fold more resistant to UVC and mitomycin C-induced killing than matched Fhit-positive cells; Fhit-/- cells exhibit greater than 5-fold increased mutation frequency after UVC survival, indicating Fhit loss promotes a mutator phenotype.","method":"Matched Fhit-positive vs. Fhit-negative cancer cell pairs and Fhit-/- vs. Fhit+/+ mouse kidney cells; clonogenic survival assays; synchronization; DNA synthesis measurement; mutation frequency assays","journal":"British journal of cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — matched cell pairs with multiple DNA damage agents and quantitative mutation frequency, single lab","pmids":["15494723"],"is_preprint":false},{"year":2015,"finding":"Fhit expression is present in the nucleus of breast cancer cells at low levels; mitogenic (EGF) stimulation increases nuclear Fhit; forced nuclear localization of Fhit (via nuclear localization sequence) increases proliferation rate and levels of cyclin D1, phospho-MAPK, and phospho-STAT3, suggesting a proliferation-promoting role for nuclear Fhit distinct from cytoplasmic tumor suppression.","method":"Subcellular fractionation; nuclear localization sequence fusion construct; proteasome inhibitor experiments; FhitY114F mutant analysis; Western blot for proliferation markers","journal":"Journal of cellular physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct localization experiments tied to functional consequences with multiple genetic approaches, single lab","pmids":["25711523"],"is_preprint":false},{"year":1998,"finding":"Drosophila melanogaster and C. elegans encode Fhit as a fusion protein with a nitrilase domain (NitFhit); the Drosophila fusion protein retains Ap3A hydrolase activity expected of an authentic Fhit homolog; in mammals, the Fhit and Nit1 functions are encoded by separate genes on different chromosomes, suggesting they collaborate in a biochemical pathway.","method":"Cloning and sequencing of Drosophila and C. elegans FHIT orthologs; in vitro Ap3A hydrolase activity assay of Drosophila fusion protein; chromosomal mapping of human and mouse NIT1 genes","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro enzymatic assay of ortholog, single lab, functional inference for mammalian pathway is proposed","pmids":["9671749"],"is_preprint":false},{"year":2021,"finding":"Tanshinone compounds (STS/TSA) directly bind FHIT protein (Kd ~268 nM) and inhibit its Ap3A hydrolase activity by competing for the substrate-binding site (IC50 ~2.2 µM); depletion of FHIT blocks tanshinone-induced apoptosis in colorectal cancer cells.","method":"Surface plasmon resonance/binding affinity measurement; in vitro Ap3A hydrolase inhibition assay; FHIT siRNA knockdown; apoptosis assay","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro binding and enzymatic assay plus genetic loss-of-function, single lab","pmids":["34108553"],"is_preprint":false},{"year":2017,"finding":"FHIT loss alters translation of cancer-associated mRNAs; ribosome profiling identified several hundred mRNAs with changed coding-region ribosome occupancy as a function of Fhit expression, including changes in translation efficiency and 5'-UTR ribosome occupancy, linking Fhit's cap-degrading hydrolase activity to post-transcriptional gene regulation.","method":"Ribosome profiling (ribo-seq) in Fhit-positive vs. Fhit-negative cells; mRNA steady-state measurements","journal":"Molecular cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genome-scale ribosome profiling with matched cell pairs, single lab, mechanistic interpretation is partially inferred","pmids":["29282095"],"is_preprint":false},{"year":2007,"finding":"Fhit expression protects against HER2-driven mammary tumor development; Fhit protein levels in cancer cell lines are reduced by EGF-dependent activation of EGFR family members (including HER2) via proteasomal degradation; heterozygous Fhit loss in HER2/neu transgenic mice increases tumor incidence.","method":"Fhit+/- x MMTV-HER2/neu mouse cross; tumor incidence assessment; proteasome inhibitor experiments in cancer cell lines; IHC of human breast carcinomas","journal":"Cell cycle (Georgetown, Tex.)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo genetic cross with functional readout plus in vitro proteasomal degradation mechanism, single lab","pmids":["17374991"],"is_preprint":false}],"current_model":"Fhit is a homodimeric Ap3A hydrolase whose enzymatic activity is dispensable for tumor suppression; it functions as a genome caretaker by regulating Thymidine Kinase 1 expression and nucleotide pool balance to prevent replication stress-induced DNA double-strand breaks, modulates mid-S-phase checkpoint proteins (Hus1/Chk1) in a Y114-dependent manner, localizes to cytoplasm and mitochondria where it stabilizes ferredoxin reductase (Fdxr) via Hsp60/Hsp10 interactions to promote ROS-induced apoptosis under oxidative stress, and suppresses oncogenic transcription by directly binding β-catenin to repress Wnt target genes; Src phosphorylates Fhit at Y114, which is required for apoptotic signaling through inhibition of the PI3K-Akt-survivin pathway and for downstream effector interactions."},"narrative":{"mechanistic_narrative":"FHIT is a genome-caretaker tumor suppressor that protects against replication stress while operating in parallel as a signaling and pro-apoptotic factor, and its biochemical hydrolase activity is dispensable for its tumor-suppressive functions [PMID:9391102, PMID:23209436]. Although recombinant FHIT is a homodimeric Ap3A hydrolase [PMID:10733886], both wild-type and active-site (His-mutant) FHIT suppress tumorigenicity, dissociating dinucleotide hydrolysis from growth suppression [PMID:9391102]. Its principal caretaker role is preventing DNA replication stress: FHIT loss causes replication fork stalling and collapse and double-strand breaks driven by dysregulated Thymidine Kinase 1 expression and thymidine triphosphate pool imbalance, defects rescued by restoring nucleotide balance and dependent on Chk1 activity but independent of ATR/ATM [PMID:23209436, PMID:23102829]. This replication stress generates single-stranded DNA that becomes a substrate for APOBEC3B-mediated mutagenesis, and nucleotide supplementation reduces APOBEC-directed mutations [PMID:25401976]. FHIT activity converges on the conserved Y114 residue, which is phosphorylated by Src and required for caspase-dependent apoptosis through inhibition of the PI3K-Akt-survivin pathway and modulation of the mid-S-phase Hus1/Chk1 checkpoint [PMID:15007172, PMID:16407838, PMID:17145874]. FHIT localizes to cytoplasm and mitochondria, where it interacts with Hsp60/Hsp10 and stabilizes ferredoxin reductase (Fdxr) to promote ROS production and apoptosis under oxidative stress [PMID:19004824, PMID:19486340]. It also represses oncogenic transcription, binding the C-terminal domain of β-catenin to repress Wnt target genes independent of hydrolase activity [PMID:18077326], and suppresses EMT and metastasis through miR-30c upregulation and downregulation of the EGFR/Src/ERK/Slug axis [PMID:25340791, PMID:24464917].","teleology":[{"year":1997,"claim":"Established that FHIT's enzymatic Ap3A hydrolase activity is separable from its tumor-suppressive function, redirecting the field away from a purely metabolic enzyme model.","evidence":"In vitro hydrolase assay with active-site mutagenesis plus nude mouse tumorigenicity assay of FHIT-transfected cells","pmids":["9391102"],"confidence":"High","gaps":["Did not identify the non-catalytic effector function responsible for tumor suppression","Mechanism of growth suppression unresolved"]},{"year":2000,"claim":"Defined the biochemical parameters of FHIT as a homodimeric Ap3A asymmetric hydrolase, providing rigorous kinetic characterization of the purified enzyme.","evidence":"Recombinant E. coli expression, purification, and Ap3A hydrolysis kinetics","pmids":["10733886"],"confidence":"High","gaps":["Does not connect enzymatic activity to any cellular function","In vivo substrate not established"]},{"year":2004,"claim":"Placed FHIT in a Src signaling pathway by identifying it as a Src substrate phosphorylated at Y114, a residue that became central to its regulatory functions.","evidence":"In vitro kinase assay, in vivo phosphorylation, and site-directed mutagenesis","pmids":["15007172"],"confidence":"High","gaps":["Functional consequence of Y114 phosphorylation not defined in this study","Single kinase identified; broader regulatory network unknown"]},{"year":2004,"claim":"Demonstrated that FHIT loss produces a mutator phenotype with resistance to DNA-damaging agents, framing FHIT as a guardian of genome integrity.","evidence":"Matched Fhit-positive/negative cancer pairs and Fhit knockout mouse cells; clonogenic survival and mutation frequency assays","pmids":["15494723"],"confidence":"Medium","gaps":["Molecular basis of the mutator phenotype not yet identified","Did not link to replication or checkpoint machinery"]},{"year":2006,"claim":"Connected FHIT's Y114-dependent apoptotic activity to suppression of the PI3K-Akt-survivin survival pathway and to mid-S-phase checkpoint modulation (Hus1/phospho-Chk1).","evidence":"Adenoviral wild-type vs. Y114 mutant FHIT, caspase and Akt activity assays, constitutively active Akt rescue, and Western blot for checkpoint proteins","pmids":["16407838","17145874"],"confidence":"High","gaps":["Direct enzymatic or binding link between FHIT and Akt/Hus1 not established","Whether Y114 phosphorylation drives or merely permits these effects unclear"]},{"year":2006,"claim":"Extended FHIT signaling output to NF-κB inhibition and to enhancement of chemotherapy-induced apoptosis via Bcl-2 family modulation, broadening its pro-apoptotic repertoire.","evidence":"Gain- and loss-of-function FHIT in colon and other cancer cells; Western blot for p-IκB-α and Bcl-2 family; caspase assays","pmids":["16733051","16231322"],"confidence":"Medium","gaps":["Direct molecular targets in NF-κB and apoptotic pathways not identified","Single-lab correlative readouts"]},{"year":2007,"claim":"Identified a direct transcriptional repression function: FHIT binds β-catenin to repress Wnt target genes independent of hydrolase activity, providing a non-enzymatic tumor-suppressive mechanism.","evidence":"Reciprocal Co-IP, ChIP, double knockdown, reporter and soft-agar assays with enzymatically inactive H96N mutant","pmids":["18077326"],"confidence":"High","gaps":["How cytoplasmic/mitochondrial FHIT accesses promoter complexes unresolved","Structural basis of β-catenin binding not defined"]},{"year":2007,"claim":"Showed FHIT protects against HER2-driven tumors and that its protein levels are downregulated by EGFR/HER2-driven proteasomal degradation, establishing a feedback link between oncogenic signaling and FHIT loss.","evidence":"Fhit+/- x MMTV-HER2/neu mouse cross; proteasome inhibitor experiments; IHC of human breast carcinomas","pmids":["17374991"],"confidence":"Medium","gaps":["E3 ligase mediating FHIT degradation not identified","Degradation signal/modification not mapped"]},{"year":2008,"claim":"Localized FHIT's pro-apoptotic, oxidative-stress function to mitochondria via Hsp60/Hsp10 chaperone interactions and stabilization of ferredoxin reductase (Fdxr), tying substrate-binding and Y114 competence to ROS-induced death.","evidence":"Chemical cross-linking, Co-IP, mutagenesis, subcellular fractionation, and ROS/apoptosis flow cytometry","pmids":["19004824","19486340"],"confidence":"High","gaps":["Mechanism of Fdxr stabilization not biochemically defined","How chaperone interaction directs mitochondrial import unclear"]},{"year":2009,"claim":"Demonstrated through double-knockout mice that FHIT and Nit1, encoded together as a NitFhit fusion in invertebrates, act through distinct but additive tumor-suppressive pathways in mammals.","evidence":"Fhit-/-Nit1-/- double-knockout mouse tumor susceptibility; fractionation; hydroxyurea/H2O2 treatment","pmids":["19479888","9671749"],"confidence":"Medium","gaps":["The distinct Nit1 pathway not molecularly defined","Whether the two ever physically cooperate in mammals unknown"]},{"year":2012,"claim":"Established the core caretaker mechanism: FHIT loss drives replication stress and double-strand breaks via TK1/dTTP pool imbalance, with damage prevention requiring the HIT domain, Y114, and Chk1 but not ATR/ATM.","evidence":"DNA combing, siRNA, TK1 and thymidine rescue, γH2AX, knockout mouse tissue, and Chk1/ATR/ATM inhibitor/knockdown","pmids":["23209436","23102829"],"confidence":"High","gaps":["How FHIT regulates TK1 expression mechanistically not defined","Connection between hydrolase HIT domain and nucleotide pool control unresolved"]},{"year":2014,"claim":"Linked FHIT loss to EMT and metastasis through two pathways: failure to upregulate miR-30c (targeting MTDH/HMGA2/VIM/FN1) and de-repression of the EGFR/Src/ERK/Slug axis.","evidence":"In vivo/in vitro invasion and metastasis assays, miR-30c target validation, and pharmacologic/genetic pathway dissection","pmids":["25340791","24464917"],"confidence":"Medium","gaps":["How FHIT controls miR-30c expression not established","Direct vs. indirect regulation of EGFR axis unclear"]},{"year":2015,"claim":"Showed FHIT-driven replication stress generates ssDNA exploited by APOBEC3B, mechanistically connecting FHIT loss to a defined mutational signature reversible by nucleotide supplementation.","evidence":"TCGA correlation with in vitro knockdown, APOBEC3B-directed TP53 mutation assay, and thymidine rescue","pmids":["25401976"],"confidence":"Medium","gaps":["Correlative tumor data not causal in vivo","Generality across mutation signatures unknown"]},{"year":2015,"claim":"Revealed a context-dependent nuclear role in which EGF-induced nuclear FHIT promotes proliferation, contrasting with its cytoplasmic tumor-suppressive activity.","evidence":"Subcellular fractionation, NLS-fusion constructs, proteasome inhibitor and Y114F mutant analysis with proliferation marker Western blots","pmids":["25711523"],"confidence":"Medium","gaps":["Reconciliation with earlier non-nuclear localization reports incomplete","Mechanism of nuclear FHIT's proliferative effect undefined"]},{"year":2017,"claim":"Connected FHIT to post-transcriptional regulation by showing FHIT status alters ribosome occupancy of hundreds of cancer-associated mRNAs.","evidence":"Ribosome profiling in matched Fhit-positive/negative cells with mRNA steady-state measurement","pmids":["29282095"],"confidence":"Medium","gaps":["Direct molecular link between FHIT hydrolase activity and translation not shown","Causal targets driving phenotype not isolated"]},{"year":2019,"claim":"Identified FHIT as a genetic modifier of BMPR2 signaling relevant to pulmonary arterial hypertension, extending its role beyond cancer.","evidence":"Genome-scale siRNA screen, Fhit-/- mouse hypoxia model, and in vitro cell dysfunction assays","pmids":["30107138"],"confidence":"Medium","gaps":["Molecular mechanism linking FHIT to BMPR2 signaling not defined","Direct interaction vs. indirect modifier role unresolved"]},{"year":2021,"claim":"Provided a pharmacological handle by showing tanshinone compounds bind FHIT and inhibit its hydrolase activity, with FHIT required for tanshinone-induced apoptosis.","evidence":"Surface plasmon resonance binding, in vitro hydrolase inhibition, FHIT siRNA, and apoptosis assay","pmids":["34108553"],"confidence":"Medium","gaps":["How hydrolase inhibition triggers apoptosis given enzyme-independent tumor suppression unclear","On-target specificity in vivo not established"]},{"year":null,"claim":"The unifying biochemical mechanism that links FHIT's catalytic HIT domain to its diverse non-enzymatic functions (TK1/nucleotide control, β-catenin repression, mitochondrial apoptosis, translation) remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structural model explaining how Y114 phosphorylation gates effector interactions","Direct in vivo substrate and the molecular route from hydrolase activity to caretaker function undefined","Apparent localization conflicts (cytoplasm/mitochondria vs. nucleus/plasma membrane) not mechanistically reconciled"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[0,16,20]},{"term_id":"GO:0140098","term_label":"catalytic activity, acting on RNA","supporting_discovery_ids":[0,16]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[4]}],"localization":[{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[5,8,15]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[8,15]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[19]}],"pathway":[{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[6,10,18]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[2,5,14]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[1,4,13]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[3,7]}],"complexes":["LEF1/TCF/β-catenin complex"],"partners":["SRC","CTNNB1","FDXR","HSPD1","HSPE1","CHEK1","HUS1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P49789","full_name":"Bis(5'-adenosyl)-triphosphatase","aliases":["AP3A hydrolase","AP3Aase","Adenosine 5'-monophosphoramidase FHIT","Adenylylsulfatase","Adenylylsulfate-ammonia adenylyltransferase","Diadenosine 5',5'''-P1,P3-triphosphate hydrolase","Dinucleosidetriphosphatase","Fragile histidine triad protein"],"length_aa":147,"mass_kda":16.9,"function":"Possesses dinucleoside triphosphate hydrolase activity (PubMed:12574506, PubMed:15182206, PubMed:8794732, PubMed:9323207, PubMed:9543008, PubMed:9576908). Cleaves P(1)-P(3)-bis(5'-adenosyl) triphosphate (Ap3A) to yield AMP and ADP (PubMed:12574506, PubMed:15182206, PubMed:8794732, PubMed:9323207, PubMed:9543008, PubMed:9576908). Can also hydrolyze P(1)-P(4)-bis(5'-adenosyl) tetraphosphate (Ap4A), but has extremely low activity with ATP (PubMed:8794732). Exhibits adenylylsulfatase activity, hydrolyzing adenosine 5'-phosphosulfate to yield AMP and sulfate (PubMed:18694747). Exhibits adenosine 5'-monophosphoramidase activity, hydrolyzing purine nucleotide phosphoramidates with a single phosphate group such as adenosine 5'monophosphoramidate (AMP-NH2) to yield AMP and NH2 (PubMed:18694747). Exhibits adenylylsulfate-ammonia adenylyltransferase, catalyzing the ammonolysis of adenosine 5'-phosphosulfate resulting in the formation of adenosine 5'-phosphoramidate (PubMed:26181368). Also catalyzes the ammonolysis of adenosine 5-phosphorofluoridate and diadenosine triphosphate (PubMed:26181368). Modulates transcriptional activation by CTNNB1 and thereby contributes to regulate the expression of genes essential for cell proliferation and survival, such as CCND1 and BIRC5 (PubMed:18077326). Plays a role in the induction of apoptosis via SRC and AKT1 signaling pathways (PubMed:16407838). Inhibits MDM2-mediated proteasomal degradation of p53/TP53 and thereby plays a role in p53/TP53-mediated apoptosis (PubMed:15313915). Induction of apoptosis depends on the ability of FHIT to bind P(1)-P(3)-bis(5'-adenosyl) triphosphate or related compounds, but does not require its catalytic activity, it may in part come from the mitochondrial form, which sensitizes the low-affinity Ca(2+) transporters, enhancing mitochondrial calcium uptake (PubMed:12574506, PubMed:19622739). Functions as a tumor suppressor (By similarity)","subcellular_location":"Cytoplasm; Mitochondrion; Nucleus","url":"https://www.uniprot.org/uniprotkb/P49789/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/FHIT","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/FHIT","total_profiled":1310},"omim":[{"mim_id":"616769","title":"NITRILASE FAMILY MEMBER 2; NIT2","url":"https://www.omim.org/entry/616769"},{"mim_id":"613984","title":"FANCD2 GENE; FANCD2","url":"https://www.omim.org/entry/613984"},{"mim_id":"609998","title":"HISTIDINE TRIAD NUCLEOTIDE-BINDING PROTEIN 3; HINT3","url":"https://www.omim.org/entry/609998"},{"mim_id":"609997","title":"HISTIDINE TRIAD NUCLEOTIDE-BINDING PROTEIN 2; HINT2","url":"https://www.omim.org/entry/609997"},{"mim_id":"606350","title":"APRATAXIN; APTX","url":"https://www.omim.org/entry/606350"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Nucleoli fibrillar center","reliability":"Approved"},{"location":"Plasma membrane","reliability":"Approved"}],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"choroid plexus","ntpm":607.4}],"url":"https://www.proteinatlas.org/search/FHIT"},"hgnc":{"alias_symbol":["FRA3B","AP3Aase"],"prev_symbol":[]},"alphafold":{"accession":"P49789","domains":[{"cath_id":"3.30.428.10","chopping":"2-143","consensus_level":"high","plddt":95.6933,"start":2,"end":143}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P49789","model_url":"https://alphafold.ebi.ac.uk/files/AF-P49789-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P49789-F1-predicted_aligned_error_v6.png","plddt_mean":95.25},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=FHIT","jax_strain_url":"https://www.jax.org/strain/search?query=FHIT"},"sequence":{"accession":"P49789","fasta_url":"https://rest.uniprot.org/uniprotkb/P49789.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P49789/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P49789"}},"corpus_meta":[{"pmid":"8620533","id":"PMC_8620533","title":"The FHIT gene 3p14.2 is abnormal in lung cancer.","date":"1996","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/8620533","citation_count":545,"is_preprint":false},{"pmid":"9391102","id":"PMC_9391102","title":"Replacement of Fhit in cancer cells suppresses tumorigenicity.","date":"1997","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/9391102","citation_count":343,"is_preprint":false},{"pmid":"8790406","id":"PMC_8790406","title":"FHIT gene alterations in head and neck squamous cell carcinomas.","date":"1996","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/8790406","citation_count":240,"is_preprint":false},{"pmid":"9012482","id":"PMC_9012482","title":"Structure and expression of the human FHIT gene in normal and tumor cells.","date":"1997","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/9012482","citation_count":208,"is_preprint":false},{"pmid":"10758156","id":"PMC_10758156","title":"Muir-Torre-like syndrome in Fhit-deficient mice.","date":"2000","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/10758156","citation_count":181,"is_preprint":false},{"pmid":"9928473","id":"PMC_9928473","title":"The role of the FHIT/FRA3B locus in cancer.","date":"1998","source":"Annual review of genetics","url":"https://pubmed.ncbi.nlm.nih.gov/9928473","citation_count":170,"is_preprint":false},{"pmid":"11248081","id":"PMC_11248081","title":"FHIT gene therapy prevents tumor development in Fhit-deficient mice.","date":"2001","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/11248081","citation_count":143,"is_preprint":false},{"pmid":"9354423","id":"PMC_9354423","title":"Loss of FHIT expression in cervical carcinoma cell lines and primary tumors.","date":"1997","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/9354423","citation_count":132,"is_preprint":false},{"pmid":"9689122","id":"PMC_9689122","title":"The hereditary renal cell carcinoma 3;8 translocation fuses FHIT to a patched-related gene, TRC8.","date":"1998","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/9689122","citation_count":128,"is_preprint":false},{"pmid":"10728669","id":"PMC_10728669","title":"Altered expression of Fhit in carcinoma and precarcinomatous lesions of the esophagus.","date":"2000","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/10728669","citation_count":121,"is_preprint":false},{"pmid":"15073846","id":"PMC_15073846","title":"The fragile genes FHIT and WWOX are inactivated coordinately in invasive breast carcinoma.","date":"2004","source":"Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/15073846","citation_count":121,"is_preprint":false},{"pmid":"12473516","id":"PMC_12473516","title":"FHIT: from gene discovery to cancer treatment and prevention.","date":"2002","source":"The Lancet. Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/12473516","citation_count":113,"is_preprint":false},{"pmid":"9349498","id":"PMC_9349498","title":"Frequent deletions of FHIT and FRA3B in Barrett's metaplasia and esophageal adenocarcinomas.","date":"1997","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/9349498","citation_count":107,"is_preprint":false},{"pmid":"25283145","id":"PMC_25283145","title":"The FHIT gene product: tumor suppressor and genome \"caretaker\".","date":"2014","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/25283145","citation_count":83,"is_preprint":false},{"pmid":"23209436","id":"PMC_23209436","title":"Initiation of genome instability and preneoplastic processes through loss of Fhit expression.","date":"2012","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23209436","citation_count":81,"is_preprint":false},{"pmid":"9679951","id":"PMC_9679951","title":"Absence or reduction of Fhit expression in most clear cell renal carcinomas.","date":"1998","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/9679951","citation_count":81,"is_preprint":false},{"pmid":"8653678","id":"PMC_8653678","title":"Aberrant FHIT transcripts in Merkel cell carcinoma.","date":"1996","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/8653678","citation_count":79,"is_preprint":false},{"pmid":"9559339","id":"PMC_9559339","title":"An FHIT tumor suppressor gene?","date":"1998","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/9559339","citation_count":72,"is_preprint":false},{"pmid":"16225988","id":"PMC_16225988","title":"Roles of FHIT and WWOX fragile genes in cancer.","date":"2005","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/16225988","citation_count":69,"is_preprint":false},{"pmid":"18077326","id":"PMC_18077326","title":"The tumor suppressor Fhit acts as a repressor of beta-catenin transcriptional activity.","date":"2007","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/18077326","citation_count":69,"is_preprint":false},{"pmid":"9671749","id":"PMC_9671749","title":"Nitrilase and Fhit homologs are encoded as fusion proteins in Drosophila melanogaster and Caenorhabditis elegans.","date":"1998","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/9671749","citation_count":64,"is_preprint":false},{"pmid":"15007172","id":"PMC_15007172","title":"Fhit is a physiological target of the protein kinase Src.","date":"2004","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/15007172","citation_count":62,"is_preprint":false},{"pmid":"10666370","id":"PMC_10666370","title":"Loss of FHIT expression in transitional cell carcinoma of the urinary bladder.","date":"2000","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/10666370","citation_count":62,"is_preprint":false},{"pmid":"14638866","id":"PMC_14638866","title":"Expression of FRA16D/WWOX and FRA3B/FHIT genes in hematopoietic malignancies.","date":"2003","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/14638866","citation_count":62,"is_preprint":false},{"pmid":"10096564","id":"PMC_10096564","title":"The FHIT gene is expressed in pancreatic ductular cells and is altered in pancreatic cancers.","date":"1999","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/10096564","citation_count":62,"is_preprint":false},{"pmid":"25340791","id":"PMC_25340791","title":"FHIT suppresses epithelial-mesenchymal transition (EMT) and metastasis in lung cancer through modulation of microRNAs.","date":"2014","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/25340791","citation_count":61,"is_preprint":false},{"pmid":"10735505","id":"PMC_10735505","title":"Loss of Fhit expression in non-small-cell lung cancer: correlation with molecular genetic abnormalities and clinicopathological features.","date":"2000","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/10735505","citation_count":61,"is_preprint":false},{"pmid":"10717620","id":"PMC_10717620","title":"The expression of Fhit protein is related inversely to disease progression in patients with breast carcinoma.","date":"2000","source":"Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/10717620","citation_count":60,"is_preprint":false},{"pmid":"12543802","id":"PMC_12543802","title":"Deletion of chromosome 3p14.2-p25 involving the VHL and FHIT genes in conventional renal cell carcinoma.","date":"2003","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/12543802","citation_count":60,"is_preprint":false},{"pmid":"16407838","id":"PMC_16407838","title":"Fhit modulation of the Akt-survivin pathway in lung cancer cells: Fhit-tyrosine 114 (Y114) is essential.","date":"2006","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/16407838","citation_count":59,"is_preprint":false},{"pmid":"10618602","id":"PMC_10618602","title":"Fhit expression in gastric adenocarcinoma: correlation with disease stage and survival.","date":"2000","source":"Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/10618602","citation_count":58,"is_preprint":false},{"pmid":"25720522","id":"PMC_25720522","title":"Aberrant gene promoter methylation of p16, FHIT, CRBP1, WWOX, and DLC-1 in Epstein-Barr virus-associated gastric carcinomas.","date":"2015","source":"Medical oncology (Northwood, London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/25720522","citation_count":56,"is_preprint":false},{"pmid":"15494723","id":"PMC_15494723","title":"Fhit-deficient normal and cancer cells are mitomycin C and UVC resistant.","date":"2004","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/15494723","citation_count":50,"is_preprint":false},{"pmid":"10999736","id":"PMC_10999736","title":"Loss of fhit expression in invasive cervical carcinomas and intraepithelial lesions associated with invasive disease.","date":"2000","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/10999736","citation_count":50,"is_preprint":false},{"pmid":"15389587","id":"PMC_15389587","title":"Involvement of the Fhit gene in the ionizing radiation-activated ATR/CHK1 pathway.","date":"2005","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/15389587","citation_count":48,"is_preprint":false},{"pmid":"14630947","id":"PMC_14630947","title":"Fragile site orthologs FHIT/FRA3B and Fhit/Fra14A2: evolutionarily conserved but highly recombinogenic.","date":"2003","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/14630947","citation_count":47,"is_preprint":false},{"pmid":"10363992","id":"PMC_10363992","title":"Reduced Fhit expression in sporadic and BRCA2-linked breast carcinomas.","date":"1999","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/10363992","citation_count":47,"is_preprint":false},{"pmid":"19086848","id":"PMC_19086848","title":"Fhit tumor suppressor: guardian of the preneoplastic genome.","date":"2008","source":"Future oncology (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/19086848","citation_count":43,"is_preprint":false},{"pmid":"9233782","id":"PMC_9233782","title":"FHIT gene alterations in esophageal cancer and ulcerative colitis (UC).","date":"1997","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/9233782","citation_count":41,"is_preprint":false},{"pmid":"24464917","id":"PMC_24464917","title":"Fhit regulates EMT targets through an EGFR/Src/ERK/Slug signaling axis in human bronchial cells.","date":"2014","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/24464917","citation_count":41,"is_preprint":false},{"pmid":"20082323","id":"PMC_20082323","title":"Pathology and biology associated with the fragile FHIT gene and gene product.","date":"2010","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20082323","citation_count":40,"is_preprint":false},{"pmid":"9614374","id":"PMC_9614374","title":"FHIT and p53 gene abnormalities in bronchioloalveolar carcinomas. Correlations with clinicopathological data and K-ras mutations.","date":"1998","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/9614374","citation_count":40,"is_preprint":false},{"pmid":"17457056","id":"PMC_17457056","title":"A Fhit-ing role in the DNA damage checkpoint response.","date":"2007","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/17457056","citation_count":39,"is_preprint":false},{"pmid":"32059763","id":"PMC_32059763","title":"RBP EIF2S2 Promotes Tumorigenesis and Progression by Regulating MYC-Mediated Inhibition via FHIT-Related Enhancers.","date":"2020","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/32059763","citation_count":39,"is_preprint":false},{"pmid":"10732756","id":"PMC_10732756","title":"Abnormalities of the FHIT gene in human oral carcinogenesis.","date":"2000","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/10732756","citation_count":38,"is_preprint":false},{"pmid":"19935706","id":"PMC_19935706","title":"Fhit regulates invasion of lung tumor cells.","date":"2009","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/19935706","citation_count":37,"is_preprint":false},{"pmid":"17145874","id":"PMC_17145874","title":"Fhit modulates the DNA damage checkpoint response.","date":"2006","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/17145874","citation_count":36,"is_preprint":false},{"pmid":"30107138","id":"PMC_30107138","title":"FHIT, a Novel Modifier Gene in Pulmonary Arterial Hypertension.","date":"2019","source":"American journal of respiratory and critical care medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30107138","citation_count":35,"is_preprint":false},{"pmid":"18221322","id":"PMC_18221322","title":"Alterations of FHIT and P53 genes in keratocystic odontogenic tumor, dentigerous and radicular cyst.","date":"2008","source":"Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology","url":"https://pubmed.ncbi.nlm.nih.gov/18221322","citation_count":35,"is_preprint":false},{"pmid":"9290948","id":"PMC_9290948","title":"FHIT gene and the FRA3B region are not involved in the genetics of renal cell carcinomas.","date":"1997","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/9290948","citation_count":35,"is_preprint":false},{"pmid":"11857493","id":"PMC_11857493","title":"Multiple molecular alterations of FHIT in betel-associated oral carcinoma.","date":"2002","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/11857493","citation_count":35,"is_preprint":false},{"pmid":"19486340","id":"PMC_19486340","title":"Fragile gene product, Fhit, in oxidative and replicative stress responses.","date":"2009","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/19486340","citation_count":34,"is_preprint":false},{"pmid":"9699672","id":"PMC_9699672","title":"The murine Fhit locus: isolation, characterization, and expression in normal and tumor cells.","date":"1998","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/9699672","citation_count":32,"is_preprint":false},{"pmid":"9671317","id":"PMC_9671317","title":"Analysis of the FHIT gene and its product in squamous cell carcinomas of the head and neck.","date":"1998","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/9671317","citation_count":32,"is_preprint":false},{"pmid":"12969785","id":"PMC_12969785","title":"Expression of Fhit, Mlh1, and P53 protein in human gallbladder carcinoma.","date":"2003","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/12969785","citation_count":30,"is_preprint":false},{"pmid":"11170287","id":"PMC_11170287","title":"Translocation breakpoints in FHIT and FRA3B in both homologs of chromosome 3 in an esophageal adenocarcinoma.","date":"2001","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/11170287","citation_count":29,"is_preprint":false},{"pmid":"20563537","id":"PMC_20563537","title":"FHIT: doubts are clear now.","date":"2010","source":"TheScientificWorldJournal","url":"https://pubmed.ncbi.nlm.nih.gov/20563537","citation_count":28,"is_preprint":false},{"pmid":"15569992","id":"PMC_15569992","title":"Inactivation of the FHIT gene favors bladder cancer development.","date":"2004","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/15569992","citation_count":28,"is_preprint":false},{"pmid":"9537583","id":"PMC_9537583","title":"Analysis of FHIT transcripts in cervical and endometrial cancers.","date":"1998","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/9537583","citation_count":28,"is_preprint":false},{"pmid":"24244712","id":"PMC_24244712","title":"Fhit deficiency-induced global genome instability promotes mutation and clonal expansion.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24244712","citation_count":27,"is_preprint":false},{"pmid":"12632095","id":"PMC_12632095","title":"FHIT expression and hypermethylation in esophageal squamous cell carcinoma.","date":"2003","source":"International journal of molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/12632095","citation_count":27,"is_preprint":false},{"pmid":"25422218","id":"PMC_25422218","title":"Folate deficiency and FHIT hypermethylation and HPV 16 infection promote cervical cancerization.","date":"2014","source":"Asian Pacific journal of cancer prevention : APJCP","url":"https://pubmed.ncbi.nlm.nih.gov/25422218","citation_count":26,"is_preprint":false},{"pmid":"19004824","id":"PMC_19004824","title":"Correlation of fragile histidine triad (Fhit) protein structural features with effector interactions and biological functions.","date":"2008","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19004824","citation_count":26,"is_preprint":false},{"pmid":"24901304","id":"PMC_24901304","title":"Replicative Stress and the FHIT Gene: Roles in Tumor Suppression, Genome Stability and Prevention of Carcinogenesis.","date":"2014","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/24901304","citation_count":26,"is_preprint":false},{"pmid":"10448301","id":"PMC_10448301","title":"FHIT gene abnormalities in both benign and malignant thyroid tumours.","date":"1999","source":"European journal of cancer (Oxford, England : 1990)","url":"https://pubmed.ncbi.nlm.nih.gov/10448301","citation_count":25,"is_preprint":false},{"pmid":"18378390","id":"PMC_18378390","title":"Hypermethylation of the 5'CpG island of the FHIT gene in clear cell renal carcinomas.","date":"2008","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/18378390","citation_count":25,"is_preprint":false},{"pmid":"11562178","id":"PMC_11562178","title":"FHIT alterations in breast cancer.","date":"2001","source":"Seminars in cancer biology","url":"https://pubmed.ncbi.nlm.nih.gov/11562178","citation_count":24,"is_preprint":false},{"pmid":"29282095","id":"PMC_29282095","title":"Impact of FHIT loss on the translation of cancer-associated mRNAs.","date":"2017","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/29282095","citation_count":24,"is_preprint":false},{"pmid":"25401976","id":"PMC_25401976","title":"FHIT loss-induced DNA damage creates optimal APOBEC substrates: Insights into APOBEC-mediated mutagenesis.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/25401976","citation_count":24,"is_preprint":false},{"pmid":"9233780","id":"PMC_9233780","title":"The FHIT gene is alternatively spliced in normal kidney and renal cell carcinoma.","date":"1997","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/9233780","citation_count":24,"is_preprint":false},{"pmid":"15141378","id":"PMC_15141378","title":"Expression of Fhit, cell adhesion molecules and matrix metalloproteinases in atypical adenomatous hyperplasia and pulmonary adenocarcinoma.","date":"2004","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/15141378","citation_count":24,"is_preprint":false},{"pmid":"10652418","id":"PMC_10652418","title":"fhit Alterations in endometrial carcinoma and hyperplasia.","date":"2000","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/10652418","citation_count":23,"is_preprint":false},{"pmid":"9170214","id":"PMC_9170214","title":"Decreased or altered expression of the FHIT gene in human leukemias.","date":"1997","source":"Stem cells (Dayton, Ohio)","url":"https://pubmed.ncbi.nlm.nih.gov/9170214","citation_count":22,"is_preprint":false},{"pmid":"14719099","id":"PMC_14719099","title":"Altered p16INK4a and Fhit expression in carcinogenesis and progression of human oral cancer.","date":"2004","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/14719099","citation_count":22,"is_preprint":false},{"pmid":"19479888","id":"PMC_19479888","title":"Nit1 and Fhit tumor suppressor activities are additive.","date":"2009","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19479888","citation_count":21,"is_preprint":false},{"pmid":"23534718","id":"PMC_23534718","title":"Expression of fragile histidine triad (FHIT) and WW-domain oxidoreductase gene (WWOX) in nasopharyngeal carcinoma.","date":"2013","source":"Asian Pacific journal of cancer prevention : APJCP","url":"https://pubmed.ncbi.nlm.nih.gov/23534718","citation_count":21,"is_preprint":false},{"pmid":"37029227","id":"PMC_37029227","title":"Acetylcholine promotes chronic stress-induced lung adenocarcinoma progression via α5-nAChR/FHIT pathway.","date":"2023","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/37029227","citation_count":20,"is_preprint":false},{"pmid":"26171037","id":"PMC_26171037","title":"Effect of FHIT loss and p53 mutation on HPV-infected lung carcinoma development.","date":"2015","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/26171037","citation_count":20,"is_preprint":false},{"pmid":"16231322","id":"PMC_16231322","title":"FHIT protein enhances paclitaxel-induced apoptosis in lung cancer cells.","date":"2006","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/16231322","citation_count":20,"is_preprint":false},{"pmid":"11920739","id":"PMC_11920739","title":"FHIT expression in clear cell renal carcinomas: versatility of protein levels and correlation with survival.","date":"2002","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/11920739","citation_count":19,"is_preprint":false},{"pmid":"16733051","id":"PMC_16733051","title":"Fhit protein inhibits cell growth by attenuating the signaling mediated by nuclear factor-kappaB in colon cancer cell lines.","date":"2006","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/16733051","citation_count":19,"is_preprint":false},{"pmid":"23102829","id":"PMC_23102829","title":"Characterization of the role of Fhit in suppression of DNA damage.","date":"2012","source":"Advances in biological regulation","url":"https://pubmed.ncbi.nlm.nih.gov/23102829","citation_count":18,"is_preprint":false},{"pmid":"17374991","id":"PMC_17374991","title":"Fhit expression protects against HER2-driven breast tumor development: unraveling the molecular interconnections.","date":"2007","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/17374991","citation_count":17,"is_preprint":false},{"pmid":"18299890","id":"PMC_18299890","title":"Frequent epigenetic silencing of the FHIT gene in penile squamous cell carcinomas.","date":"2008","source":"Virchows Archiv : an international journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/18299890","citation_count":17,"is_preprint":false},{"pmid":"11768238","id":"PMC_11768238","title":"Distribution of Fhit protein in rat tissues and its intracellular localization.","date":"2001","source":"Molecular and cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11768238","citation_count":16,"is_preprint":false},{"pmid":"16085127","id":"PMC_16085127","title":"A mouse model of the fragile gene FHIT: From carcinogenesis to gene therapy and cancer prevention.","date":"2005","source":"Mutation research","url":"https://pubmed.ncbi.nlm.nih.gov/16085127","citation_count":16,"is_preprint":false},{"pmid":"16616810","id":"PMC_16616810","title":"Effect of inducible FHIT and p53 expression in the Calu-1 lung cancer cell line.","date":"2006","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/16616810","citation_count":16,"is_preprint":false},{"pmid":"21711110","id":"PMC_21711110","title":"microRNA-143 protects cells from DNA damage-induced killing by downregulating FHIT expression.","date":"2011","source":"Cancer biotherapy & radiopharmaceuticals","url":"https://pubmed.ncbi.nlm.nih.gov/21711110","citation_count":16,"is_preprint":false},{"pmid":"10571505","id":"PMC_10571505","title":"Loss or reduction of Fhit expression in renal neoplasias: correlation with histogenic class.","date":"1999","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/10571505","citation_count":16,"is_preprint":false},{"pmid":"27773744","id":"PMC_27773744","title":"Fhit and Wwox loss-associated genome instability: A genome caretaker one-two punch.","date":"2016","source":"Advances in biological regulation","url":"https://pubmed.ncbi.nlm.nih.gov/27773744","citation_count":15,"is_preprint":false},{"pmid":"34108553","id":"PMC_34108553","title":"Tanshinones induce tumor cell apoptosis via directly targeting FHIT.","date":"2021","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/34108553","citation_count":15,"is_preprint":false},{"pmid":"12534361","id":"PMC_12534361","title":"Immunohistochemical detection of cell cycle regulators, Fhit protein and apoptotic cells in parathyroid lesions.","date":"2003","source":"European journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/12534361","citation_count":15,"is_preprint":false},{"pmid":"9744498","id":"PMC_9744498","title":"Aberrant transcripts of the FHIT gene are expressed in normal and leukaemic haemopoietic cells.","date":"1998","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/9744498","citation_count":15,"is_preprint":false},{"pmid":"25711523","id":"PMC_25711523","title":"Fhit Nuclear Import Following EGF Stimulation Sustains Proliferation of Breast Cancer Cells.","date":"2015","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/25711523","citation_count":15,"is_preprint":false},{"pmid":"9730598","id":"PMC_9730598","title":"FHIT gene transcript alterations occur frequently in myeloproliferative and myelodysplastic diseases.","date":"1998","source":"Cytogenetics and cell genetics","url":"https://pubmed.ncbi.nlm.nih.gov/9730598","citation_count":15,"is_preprint":false},{"pmid":"16547961","id":"PMC_16547961","title":"Diadenosines as FHIT-ness instructors.","date":"2006","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/16547961","citation_count":14,"is_preprint":false},{"pmid":"10204806","id":"PMC_10204806","title":"Expression of FHIT in primary cultures of human epithelial ovarian tumors and malignant ovarian ascites.","date":"1999","source":"Molecular carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/10204806","citation_count":14,"is_preprint":false},{"pmid":"12218081","id":"PMC_12218081","title":"Preferential loss of Fhit expression in signet-ring cell and Krukenberg subtypes of gastric cancer.","date":"2002","source":"Laboratory investigation; a journal of technical methods and pathology","url":"https://pubmed.ncbi.nlm.nih.gov/12218081","citation_count":14,"is_preprint":false},{"pmid":"10733886","id":"PMC_10733886","title":"Expression in Escherichia coli and simple purification of human Fhit protein.","date":"2000","source":"Protein expression and purification","url":"https://pubmed.ncbi.nlm.nih.gov/10733886","citation_count":14,"is_preprint":false},{"pmid":"19578286","id":"PMC_19578286","title":"Aberrations of the FHIT gene and Fhit protein in canine lymphoma cell lines.","date":"2009","source":"The Journal of veterinary medical science","url":"https://pubmed.ncbi.nlm.nih.gov/19578286","citation_count":14,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":49764,"output_tokens":6006,"usd":0.119691,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":14743,"output_tokens":5415,"usd":0.104545,"stage2_stop_reason":"end_turn"},"total_usd":0.224236,"stage1_batch_id":"msgbatch_01AsR7g8dGTEiEw9U83bJeWn","stage2_batch_id":"msgbatch_01YV5ZyxtFNUZEjxRcpd9jzb","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1997,\n      \"finding\": \"Fhit hydrolyzes dinucleotide 5',5'''-P1,P3-triphosphate (Ap3A) in vitro; mutation of the central histidine abolishes hydrolase activity. However, both wild-type and hydrolase-dead Fhit mutant proteins suppressed tumorigenicity in nude mice, indicating that Ap3A hydrolysis is not required for tumor suppression.\",\n      \"method\": \"In vitro enzymatic assay; active-site mutagenesis; nude mouse tumorigenicity assay with FHIT-transfected cancer cell lines\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro enzymatic reconstitution combined with active-site mutagenesis and in vivo tumorigenicity assay in a single rigorous study\",\n      \"pmids\": [\"9391102\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Fhit is a physiological substrate of the Src protein kinase; Src phosphorylates Fhit at tyrosine 114 (Y114) both in vitro and in vivo, placing Fhit in a Src-dependent signaling pathway.\",\n      \"method\": \"In vitro kinase assay; in vivo phosphorylation; site-directed mutagenesis identifying Y114 as the phosphorylation site\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro kinase assay plus in vivo phosphorylation with site identification, single lab but two orthogonal methods\",\n      \"pmids\": [\"15007172\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Fhit Y114 is essential for caspase-dependent apoptosis; wild-type Fhit (but not Y114 mutants) inhibits Akt activity and reduces survivin expression in lung cancer cells, placing Fhit upstream of the PI3K-Akt-survivin survival pathway.\",\n      \"method\": \"Adenoviral expression of wild-type vs. Y114 mutant FHIT in lung cancer cell lines; caspase activation assays; expression profiling; Akt activity measurement in vitro and in vivo; constitutively active Akt rescue experiment\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (expression profiling, kinase activity, rescue with constitutively active Akt, mutagenesis) in a single focused study\",\n      \"pmids\": [\"16407838\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Fhit modulates expression of checkpoint proteins Hus1 and phospho-Chk1 at mid-S phase; exogenous Fhit introduction induces apoptosis in esophageal cancer cells through this checkpoint modulation, and Y114 mutation abolishes this function.\",\n      \"method\": \"Exogenous Fhit expression in cancer cell lines; Western blot for Hus1 and phospho-Chk1; Y114 mutagenesis; apoptosis assays\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean KO/overexpression with defined molecular readout and mutagenesis, single lab\",\n      \"pmids\": [\"17145874\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Fhit associates with the LEF1/TCF/β-catenin complex by directly binding to the β-catenin C-terminal domain, repressing transcription of Wnt target genes (cyclin D1, axin2, MMP-14, survivin); this function does not require Fhit's hydrolase activity; Fhit/β-catenin complexes are recruited to target gene promoters.\",\n      \"method\": \"Co-immunoprecipitation; ChIP; Fhit knockdown and double knockdown with β-catenin; reporter assays; soft-agar anchorage-independent growth assay; enzymatically inactive Fhit-H96N mutant\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP, ChIP, genetic rescue experiments, mutagenesis, and functional assay in one study\",\n      \"pmids\": [\"18077326\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Fhit interacts with Hsp60/Hsp10 chaperone machinery (identified by chemical cross-linking and immunoprecipitation), and with ferredoxin reductase (Fdxr) in mitochondria; Fhit binds and stabilizes Fdxr, and this interaction promotes reactive oxygen species production and apoptosis under oxidative stress. Substrate-binding and Y114 phosphorylation-competent Fhit mutants are required for Hsp60 and Fdxr interactions and for mitochondrial localization.\",\n      \"method\": \"Chemical cross-linking; co-immunoprecipitation; mutagenesis of substrate-binding and Y114 residues; subcellular fractionation; flow cytometry for ROS and apoptosis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — chemical cross-linking plus co-IP, mutagenesis, subcellular fractionation, and functional ROS/apoptosis assays in one rigorous study\",\n      \"pmids\": [\"19004824\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Loss of Fhit expression causes DNA replication stress-induced double-strand breaks; Fhit-deficient cells show defective replication fork progression (fork stalling and collapse by DNA combing); the mechanism involves Fhit regulation of Thymidine Kinase 1 (TK1) expression and thymidine triphosphate pool levels—restoration of nucleotide balance rescues replication defects and suppresses DNA breakage.\",\n      \"method\": \"DNA combing (single-molecule replication fork analysis); siRNA knockdown; TK1 expression measurement; thymidine supplementation rescue; γH2AX foci; Fhit knockout mouse tissue analysis\",\n      \"journal\": \"PLoS genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — multiple orthogonal methods (DNA combing, molecular rescue, in vivo knockout tissue), replicated across normal, transformed, and cancer-derived cell lines\",\n      \"pmids\": [\"23209436\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Fhit's ability to prevent DNA damage requires a functional HIT domain and Y114 residue, and depends on Chk1 kinase activity but is independent of ATR or ATM kinases, suggesting Fhit and Chk1 cooperate to prevent replication stress-induced DNA damage.\",\n      \"method\": \"HIT domain mutants; Y114 mutant; Chk1, ATR, ATM inhibitors/knockdown; DNA damage markers in Fhit-deficient cells\",\n      \"journal\": \"Advances in biological regulation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacologic and genetic dissection of pathway dependencies, single lab, multiple inhibitor approaches\",\n      \"pmids\": [\"23102829\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Fhit localizes to both cytoplasm and mitochondria (but not nuclei) in normal tissue; Fhit-positive cancer cells exposed to oxidative stress (H2O2) produce higher levels of apoptosis-inducing ROS than matched Fhit-negative cells, a function linked to Fhit stabilization of mitochondrial Fdxr.\",\n      \"method\": \"Subcellular fractionation of normal and cancer cells; H2O2 treatment; ROS measurement; apoptosis assays in matched Fhit-positive vs. Fhit-negative cancer cells\",\n      \"journal\": \"Cancer science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — fractionation with functional consequence, matched cell pair comparisons, single lab\",\n      \"pmids\": [\"19486340\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Fhit protein is localized to the nucleus and plasma membrane in rat tissues (by differential and density-gradient centrifugation of subcellular fractions), with expression levels varying by tissue type (highest in spleen and brain).\",\n      \"method\": \"Differential and density-gradient centrifugation; immunoblot of subcellular fractions; RT-PCR\",\n      \"journal\": \"Molecular and cellular biochemistry\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single fractionation study without functional consequence linked to localization; contradicted by later mitochondrial/cytoplasmic localization findings\",\n      \"pmids\": [\"11768238\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Fhit loss-induced replication stress creates single-stranded DNA substrates optimal for APOBEC3B-mediated mutagenesis; FHIT-low/APOBEC3B-high tumors show significantly more APOBEC-signature mutations, and thymidine supplementation (rescuing TK1-dependent nucleotide imbalance) reduces APOBEC-directed TP53 mutations in vitro.\",\n      \"method\": \"TCGA data analysis correlated with in vitro Fhit knockdown; APOBEC3B-directed mutation assay in TP53; thymidine supplementation rescue\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mechanistic in vitro rescue experiment combined with TCGA correlative data, single lab\",\n      \"pmids\": [\"25401976\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"FHIT suppresses EMT and metastasis in lung cancer by upregulating miR-30c, which directly targets metastasis genes MTDH, HMGA2, VIM, and FN1; enforced FHIT expression reduces invasiveness in vivo and in vitro.\",\n      \"method\": \"In vivo metastasis assay; in vitro invasion assay; miR-30c target validation; ectopic FHIT expression; FHIT/miR-30c/target expression correlation in human tumors\",\n      \"journal\": \"PLoS genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (in vivo and in vitro assays, miRNA target validation), single lab\",\n      \"pmids\": [\"25340791\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Fhit silencing in bronchial cells induces overexpression of MMP-9 and vimentin (EMT markers) via an EGFR/Src/ERK/Slug signaling axis; ectopic Fhit expression in Fhit-deficient lung cancer cells downregulates this pathway.\",\n      \"method\": \"Fhit siRNA knockdown; pharmacologic inhibitors (PD98059, PP1, gefitinib); anti-EGFR antibody; Slug knockdown; ectopic Fhit expression; IHC of human tumor specimens for Fhit/phospho-EGFR correlation\",\n      \"journal\": \"Molecular cancer research : MCR\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacologic and genetic pathway dissection with multiple inhibitors, single lab\",\n      \"pmids\": [\"24464917\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Fhit expression inhibits NF-κB signaling in colon cancer cells by reducing phosphorylation of IκB-α; FHIT-expressing cells show reduced basal p-IκB-α and attenuated NF-κB p65 phosphorylation in response to TNF-α.\",\n      \"method\": \"Stable FHIT transfection; FHIT siRNA knockdown; Western blot for IKK complex and p-IκB-α; TNF-α stimulation; NF-κB inhibitor sensitivity assays\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain- and loss-of-function experiments with defined molecular readout, single lab\",\n      \"pmids\": [\"16733051\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Fhit expression enhances paclitaxel-induced apoptosis through activation of caspase-3 and caspase-7 (but not caspase-8) and modulation of Bcl-2 family proteins (downregulation of Bcl-2/Bcl-xL; upregulation of Bax/Bad); this effect is reversed by FHIT siRNA.\",\n      \"method\": \"Stable FHIT transfection; FHIT siRNA; caspase activity assays; Western blot for Bcl-2 family; pan-caspase inhibitor\",\n      \"journal\": \"International journal of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain- and loss-of-function with multiple molecular readouts, single lab\",\n      \"pmids\": [\"16231322\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Fhit and Nit1 tumor suppressor activities are additive in vivo (double-knockout mice develop more tumors than single knockouts), but Fhit and Nit1 affect distinct signal pathways in mammals; both proteins localize to cytoplasm and mitochondria but not nuclei.\",\n      \"method\": \"Fhit(-/-)Nit1(-/-) double-knockout mouse tumor susceptibility study; subcellular localization by fractionation; hydroxyurea and H2O2 treatment of double-deficient cells\",\n      \"journal\": \"Journal of cellular biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis via double-knockout mouse model with defined phenotypic readout, single lab\",\n      \"pmids\": [\"19479888\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Recombinant human Fhit protein is a homodimeric Ap3A asymmetric hydrolase with Km = 0.9 µM and kcat = 7.2 s⁻¹ per monomer, as measured by in vitro enzymatic assay of E. coli-expressed purified protein.\",\n      \"method\": \"Recombinant protein expression in E. coli; His-tag purification; in vitro enzymatic assay (Ap3A hydrolysis kinetics)\",\n      \"journal\": \"Protein expression and purification\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — rigorous in vitro reconstitution with kinetic characterization of purified protein, single lab\",\n      \"pmids\": [\"10733886\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"FHIT acts as a modifier of BMPR2 signaling; FHIT reduction is associated with endothelial and smooth muscle cell dysfunction in pulmonary arterial hypertension, and Fhit-/- mice show exaggerated hypoxic pulmonary hypertension and failed recovery.\",\n      \"method\": \"siRNA high-throughput screen of >20,000 genes identifying FHIT as BMPR2 modifier; Fhit-/- mouse hypoxia model; in vitro cell dysfunction assays\",\n      \"journal\": \"American journal of respiratory and critical care medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genome-scale screen with in vivo validation in knockout mice, single lab\",\n      \"pmids\": [\"30107138\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Fhit-deficient cells (human cancer and Fhit-/- mouse) are ~10-fold more resistant to UVC and mitomycin C-induced killing than matched Fhit-positive cells; Fhit-/- cells exhibit greater than 5-fold increased mutation frequency after UVC survival, indicating Fhit loss promotes a mutator phenotype.\",\n      \"method\": \"Matched Fhit-positive vs. Fhit-negative cancer cell pairs and Fhit-/- vs. Fhit+/+ mouse kidney cells; clonogenic survival assays; synchronization; DNA synthesis measurement; mutation frequency assays\",\n      \"journal\": \"British journal of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — matched cell pairs with multiple DNA damage agents and quantitative mutation frequency, single lab\",\n      \"pmids\": [\"15494723\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Fhit expression is present in the nucleus of breast cancer cells at low levels; mitogenic (EGF) stimulation increases nuclear Fhit; forced nuclear localization of Fhit (via nuclear localization sequence) increases proliferation rate and levels of cyclin D1, phospho-MAPK, and phospho-STAT3, suggesting a proliferation-promoting role for nuclear Fhit distinct from cytoplasmic tumor suppression.\",\n      \"method\": \"Subcellular fractionation; nuclear localization sequence fusion construct; proteasome inhibitor experiments; FhitY114F mutant analysis; Western blot for proliferation markers\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct localization experiments tied to functional consequences with multiple genetic approaches, single lab\",\n      \"pmids\": [\"25711523\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Drosophila melanogaster and C. elegans encode Fhit as a fusion protein with a nitrilase domain (NitFhit); the Drosophila fusion protein retains Ap3A hydrolase activity expected of an authentic Fhit homolog; in mammals, the Fhit and Nit1 functions are encoded by separate genes on different chromosomes, suggesting they collaborate in a biochemical pathway.\",\n      \"method\": \"Cloning and sequencing of Drosophila and C. elegans FHIT orthologs; in vitro Ap3A hydrolase activity assay of Drosophila fusion protein; chromosomal mapping of human and mouse NIT1 genes\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro enzymatic assay of ortholog, single lab, functional inference for mammalian pathway is proposed\",\n      \"pmids\": [\"9671749\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Tanshinone compounds (STS/TSA) directly bind FHIT protein (Kd ~268 nM) and inhibit its Ap3A hydrolase activity by competing for the substrate-binding site (IC50 ~2.2 µM); depletion of FHIT blocks tanshinone-induced apoptosis in colorectal cancer cells.\",\n      \"method\": \"Surface plasmon resonance/binding affinity measurement; in vitro Ap3A hydrolase inhibition assay; FHIT siRNA knockdown; apoptosis assay\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro binding and enzymatic assay plus genetic loss-of-function, single lab\",\n      \"pmids\": [\"34108553\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"FHIT loss alters translation of cancer-associated mRNAs; ribosome profiling identified several hundred mRNAs with changed coding-region ribosome occupancy as a function of Fhit expression, including changes in translation efficiency and 5'-UTR ribosome occupancy, linking Fhit's cap-degrading hydrolase activity to post-transcriptional gene regulation.\",\n      \"method\": \"Ribosome profiling (ribo-seq) in Fhit-positive vs. Fhit-negative cells; mRNA steady-state measurements\",\n      \"journal\": \"Molecular cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genome-scale ribosome profiling with matched cell pairs, single lab, mechanistic interpretation is partially inferred\",\n      \"pmids\": [\"29282095\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Fhit expression protects against HER2-driven mammary tumor development; Fhit protein levels in cancer cell lines are reduced by EGF-dependent activation of EGFR family members (including HER2) via proteasomal degradation; heterozygous Fhit loss in HER2/neu transgenic mice increases tumor incidence.\",\n      \"method\": \"Fhit+/- x MMTV-HER2/neu mouse cross; tumor incidence assessment; proteasome inhibitor experiments in cancer cell lines; IHC of human breast carcinomas\",\n      \"journal\": \"Cell cycle (Georgetown, Tex.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo genetic cross with functional readout plus in vitro proteasomal degradation mechanism, single lab\",\n      \"pmids\": [\"17374991\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"Fhit is a homodimeric Ap3A hydrolase whose enzymatic activity is dispensable for tumor suppression; it functions as a genome caretaker by regulating Thymidine Kinase 1 expression and nucleotide pool balance to prevent replication stress-induced DNA double-strand breaks, modulates mid-S-phase checkpoint proteins (Hus1/Chk1) in a Y114-dependent manner, localizes to cytoplasm and mitochondria where it stabilizes ferredoxin reductase (Fdxr) via Hsp60/Hsp10 interactions to promote ROS-induced apoptosis under oxidative stress, and suppresses oncogenic transcription by directly binding β-catenin to repress Wnt target genes; Src phosphorylates Fhit at Y114, which is required for apoptotic signaling through inhibition of the PI3K-Akt-survivin pathway and for downstream effector interactions.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"FHIT is a genome-caretaker tumor suppressor that protects against replication stress while operating in parallel as a signaling and pro-apoptotic factor, and its biochemical hydrolase activity is dispensable for its tumor-suppressive functions [#0, #6]. Although recombinant FHIT is a homodimeric Ap3A hydrolase [#16], both wild-type and active-site (His-mutant) FHIT suppress tumorigenicity, dissociating dinucleotide hydrolysis from growth suppression [#0]. Its principal caretaker role is preventing DNA replication stress: FHIT loss causes replication fork stalling and collapse and double-strand breaks driven by dysregulated Thymidine Kinase 1 expression and thymidine triphosphate pool imbalance, defects rescued by restoring nucleotide balance and dependent on Chk1 activity but independent of ATR/ATM [#6, #7]. This replication stress generates single-stranded DNA that becomes a substrate for APOBEC3B-mediated mutagenesis, and nucleotide supplementation reduces APOBEC-directed mutations [#10]. FHIT activity converges on the conserved Y114 residue, which is phosphorylated by Src and required for caspase-dependent apoptosis through inhibition of the PI3K-Akt-survivin pathway and modulation of the mid-S-phase Hus1/Chk1 checkpoint [#1, #2, #3]. FHIT localizes to cytoplasm and mitochondria, where it interacts with Hsp60/Hsp10 and stabilizes ferredoxin reductase (Fdxr) to promote ROS production and apoptosis under oxidative stress [#5, #8]. It also represses oncogenic transcription, binding the C-terminal domain of \\u03b2-catenin to repress Wnt target genes independent of hydrolase activity [#4], and suppresses EMT and metastasis through miR-30c upregulation and downregulation of the EGFR/Src/ERK/Slug axis [#11, #12].\",\n  \"teleology\": [\n    {\n      \"year\": 1997,\n      \"claim\": \"Established that FHIT's enzymatic Ap3A hydrolase activity is separable from its tumor-suppressive function, redirecting the field away from a purely metabolic enzyme model.\",\n      \"evidence\": \"In vitro hydrolase assay with active-site mutagenesis plus nude mouse tumorigenicity assay of FHIT-transfected cells\",\n      \"pmids\": [\"9391102\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not identify the non-catalytic effector function responsible for tumor suppression\", \"Mechanism of growth suppression unresolved\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Defined the biochemical parameters of FHIT as a homodimeric Ap3A asymmetric hydrolase, providing rigorous kinetic characterization of the purified enzyme.\",\n      \"evidence\": \"Recombinant E. coli expression, purification, and Ap3A hydrolysis kinetics\",\n      \"pmids\": [\"10733886\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not connect enzymatic activity to any cellular function\", \"In vivo substrate not established\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Placed FHIT in a Src signaling pathway by identifying it as a Src substrate phosphorylated at Y114, a residue that became central to its regulatory functions.\",\n      \"evidence\": \"In vitro kinase assay, in vivo phosphorylation, and site-directed mutagenesis\",\n      \"pmids\": [\"15007172\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of Y114 phosphorylation not defined in this study\", \"Single kinase identified; broader regulatory network unknown\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Demonstrated that FHIT loss produces a mutator phenotype with resistance to DNA-damaging agents, framing FHIT as a guardian of genome integrity.\",\n      \"evidence\": \"Matched Fhit-positive/negative cancer pairs and Fhit knockout mouse cells; clonogenic survival and mutation frequency assays\",\n      \"pmids\": [\"15494723\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular basis of the mutator phenotype not yet identified\", \"Did not link to replication or checkpoint machinery\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Connected FHIT's Y114-dependent apoptotic activity to suppression of the PI3K-Akt-survivin survival pathway and to mid-S-phase checkpoint modulation (Hus1/phospho-Chk1).\",\n      \"evidence\": \"Adenoviral wild-type vs. Y114 mutant FHIT, caspase and Akt activity assays, constitutively active Akt rescue, and Western blot for checkpoint proteins\",\n      \"pmids\": [\"16407838\", \"17145874\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct enzymatic or binding link between FHIT and Akt/Hus1 not established\", \"Whether Y114 phosphorylation drives or merely permits these effects unclear\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Extended FHIT signaling output to NF-\\u03baB inhibition and to enhancement of chemotherapy-induced apoptosis via Bcl-2 family modulation, broadening its pro-apoptotic repertoire.\",\n      \"evidence\": \"Gain- and loss-of-function FHIT in colon and other cancer cells; Western blot for p-I\\u03baB-\\u03b1 and Bcl-2 family; caspase assays\",\n      \"pmids\": [\"16733051\", \"16231322\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct molecular targets in NF-\\u03baB and apoptotic pathways not identified\", \"Single-lab correlative readouts\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Identified a direct transcriptional repression function: FHIT binds \\u03b2-catenin to repress Wnt target genes independent of hydrolase activity, providing a non-enzymatic tumor-suppressive mechanism.\",\n      \"evidence\": \"Reciprocal Co-IP, ChIP, double knockdown, reporter and soft-agar assays with enzymatically inactive H96N mutant\",\n      \"pmids\": [\"18077326\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How cytoplasmic/mitochondrial FHIT accesses promoter complexes unresolved\", \"Structural basis of \\u03b2-catenin binding not defined\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Showed FHIT protects against HER2-driven tumors and that its protein levels are downregulated by EGFR/HER2-driven proteasomal degradation, establishing a feedback link between oncogenic signaling and FHIT loss.\",\n      \"evidence\": \"Fhit+/- x MMTV-HER2/neu mouse cross; proteasome inhibitor experiments; IHC of human breast carcinomas\",\n      \"pmids\": [\"17374991\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"E3 ligase mediating FHIT degradation not identified\", \"Degradation signal/modification not mapped\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Localized FHIT's pro-apoptotic, oxidative-stress function to mitochondria via Hsp60/Hsp10 chaperone interactions and stabilization of ferredoxin reductase (Fdxr), tying substrate-binding and Y114 competence to ROS-induced death.\",\n      \"evidence\": \"Chemical cross-linking, Co-IP, mutagenesis, subcellular fractionation, and ROS/apoptosis flow cytometry\",\n      \"pmids\": [\"19004824\", \"19486340\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of Fdxr stabilization not biochemically defined\", \"How chaperone interaction directs mitochondrial import unclear\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Demonstrated through double-knockout mice that FHIT and Nit1, encoded together as a NitFhit fusion in invertebrates, act through distinct but additive tumor-suppressive pathways in mammals.\",\n      \"evidence\": \"Fhit-/-Nit1-/- double-knockout mouse tumor susceptibility; fractionation; hydroxyurea/H2O2 treatment\",\n      \"pmids\": [\"19479888\", \"9671749\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"The distinct Nit1 pathway not molecularly defined\", \"Whether the two ever physically cooperate in mammals unknown\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Established the core caretaker mechanism: FHIT loss drives replication stress and double-strand breaks via TK1/dTTP pool imbalance, with damage prevention requiring the HIT domain, Y114, and Chk1 but not ATR/ATM.\",\n      \"evidence\": \"DNA combing, siRNA, TK1 and thymidine rescue, \\u03b3H2AX, knockout mouse tissue, and Chk1/ATR/ATM inhibitor/knockdown\",\n      \"pmids\": [\"23209436\", \"23102829\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How FHIT regulates TK1 expression mechanistically not defined\", \"Connection between hydrolase HIT domain and nucleotide pool control unresolved\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Linked FHIT loss to EMT and metastasis through two pathways: failure to upregulate miR-30c (targeting MTDH/HMGA2/VIM/FN1) and de-repression of the EGFR/Src/ERK/Slug axis.\",\n      \"evidence\": \"In vivo/in vitro invasion and metastasis assays, miR-30c target validation, and pharmacologic/genetic pathway dissection\",\n      \"pmids\": [\"25340791\", \"24464917\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How FHIT controls miR-30c expression not established\", \"Direct vs. indirect regulation of EGFR axis unclear\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Showed FHIT-driven replication stress generates ssDNA exploited by APOBEC3B, mechanistically connecting FHIT loss to a defined mutational signature reversible by nucleotide supplementation.\",\n      \"evidence\": \"TCGA correlation with in vitro knockdown, APOBEC3B-directed TP53 mutation assay, and thymidine rescue\",\n      \"pmids\": [\"25401976\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Correlative tumor data not causal in vivo\", \"Generality across mutation signatures unknown\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Revealed a context-dependent nuclear role in which EGF-induced nuclear FHIT promotes proliferation, contrasting with its cytoplasmic tumor-suppressive activity.\",\n      \"evidence\": \"Subcellular fractionation, NLS-fusion constructs, proteasome inhibitor and Y114F mutant analysis with proliferation marker Western blots\",\n      \"pmids\": [\"25711523\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Reconciliation with earlier non-nuclear localization reports incomplete\", \"Mechanism of nuclear FHIT's proliferative effect undefined\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Connected FHIT to post-transcriptional regulation by showing FHIT status alters ribosome occupancy of hundreds of cancer-associated mRNAs.\",\n      \"evidence\": \"Ribosome profiling in matched Fhit-positive/negative cells with mRNA steady-state measurement\",\n      \"pmids\": [\"29282095\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct molecular link between FHIT hydrolase activity and translation not shown\", \"Causal targets driving phenotype not isolated\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Identified FHIT as a genetic modifier of BMPR2 signaling relevant to pulmonary arterial hypertension, extending its role beyond cancer.\",\n      \"evidence\": \"Genome-scale siRNA screen, Fhit-/- mouse hypoxia model, and in vitro cell dysfunction assays\",\n      \"pmids\": [\"30107138\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular mechanism linking FHIT to BMPR2 signaling not defined\", \"Direct interaction vs. indirect modifier role unresolved\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Provided a pharmacological handle by showing tanshinone compounds bind FHIT and inhibit its hydrolase activity, with FHIT required for tanshinone-induced apoptosis.\",\n      \"evidence\": \"Surface plasmon resonance binding, in vitro hydrolase inhibition, FHIT siRNA, and apoptosis assay\",\n      \"pmids\": [\"34108553\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How hydrolase inhibition triggers apoptosis given enzyme-independent tumor suppression unclear\", \"On-target specificity in vivo not established\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The unifying biochemical mechanism that links FHIT's catalytic HIT domain to its diverse non-enzymatic functions (TK1/nucleotide control, \\u03b2-catenin repression, mitochondrial apoptosis, translation) remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structural model explaining how Y114 phosphorylation gates effector interactions\", \"Direct in vivo substrate and the molecular route from hydrolase activity to caretaker function undefined\", \"Apparent localization conflicts (cytoplasm/mitochondria vs. nucleus/plasma membrane) not mechanistically reconciled\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [0, 16, 20]},\n      {\"term_id\": \"GO:0140098\", \"supporting_discovery_ids\": [0, 16]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [4]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [5, 8, 15]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [8, 15]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [19]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [6, 10, 18]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [2, 5, 14]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [1, 4, 13]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [3, 7]}\n    ],\n    \"complexes\": [\"LEF1/TCF/\\u03b2-catenin complex\"],\n    \"partners\": [\"SRC\", \"CTNNB1\", \"FDXR\", \"HSPD1\", \"HSPE1\", \"CHEK1\", \"HUS1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":7,"faith_pct":85.71428571428571}}